CD209 and cancer: Among the dendritic cell subset markers of the monocyte-derived dendritic cells, it is noteworthy that CD1A mRNA counts were also found to be associated with the risk of relapse and cancer progression, while CD209 was associated only with an increase in SPP1 levels.